| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Istituto Technologie Biomediche Avanzate-Consiglio Nazionale delle Ricerche, Università di Milano, Istituto Scientifico H San Raffaele, Milan [G. P., P. M., F. Z., E. V., F. S., C. R., F. F.]; Società Prodotti Antibiotici, Milan [F. C.]; Sorin Biomedica, Saluggia [E. S.]; and Dipartimento di Biologia e Genetica per le Scienze Mediche, Università degli Studi di Milano, Milan [L. L., M. M., A. G. S.], Italy
We described a method to postlabel, in vivo, biotinylated monoclonal antibodies pretargeted onto tumor deposits when most of the non-tumorbound antibodies have already been cleared as avidin-bound complexes.
The application of this principle to tumor detection by immunoscintigraphy was tested in 20 patients with histologically documented cancer and increased circulating carcinoembryonic antigen levels. One mg of biotinylated anti-carcinoembryonic antigen monoclonal antibody (FO23C5) was administered i.v. (first step). After 3 days, 4–6 mg of cold avidin were injected i.v. (second step), followed 48 h later by 0.2–0.3 mg of a biotin derivative labeled with 111In (2–3 mCi) (third step).
No evidence of toxicity was observed. Whole body radioactivity distribution was measured in five patients at various intervals postinjection by the conjugate counting technique. Tumors and metastases were detected in 18 of 19 patients (the remaining patient was a true negative) within 3 h after administration of 111In-biotin by planar or single photon emmission tomography imaging. At the time of imaging, tumor/blood pool ratio was 5.5 ± 3.2, and tumor/liver ratio was 6.7 ± 3.9. Blood clearance of 111In-biotin was multiexponential, with the fast component having a t
of 5 ± 3 min. Urinary excretion of radioactivity over 3 h was 63.5 ± 4.9% of the injected dose. Radioactivity at 3 h was 6.5 ± 1.8% in blood, 1.6 ± 0.3% in the kidney, and 2.4 ± 0.6% in the liver.
This approach represents an improvement in immunoscintigraphic techniques for tumor localization. The potential use for radioimmunotherapy is discussed.
1 This work was supported in part by grants from the Consiglio Nazionale delle Ricerche.
2 To whom requests for reprints should be addressed, at Department of Nuclear Medicine, Istituto Scientifico H San Raffaele, via Olgettina 60, I-20132 Milan, Italy.
Received 2/ 4/91. Accepted 8/15/91.
This article has been cited by other articles:
|
|
 |
|
  F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 657 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Pagel, N. Hedin, L. Drouet, B. L. Wood, A. Pantelias, Y. Lin, D. K. Hamlin, D. S. Wilbur, A. K. Gopal, D. Green, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy Blood, February 15, 2008; 111(4): 2261 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab Cancer Res., November 1, 2007; 67(21): 10556 - 10563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tolmachev, A. Orlova, R. Pehrson, J. Galli, B. Baastrup, K. Andersson, M. Sandstrom, D. Rosik, J. Carlsson, H. Lundqvist, et al. Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule Cancer Res., March 15, 2007; 67(6): 2773 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Macor, D. Mezzanzanica, C. Cossetti, P. Alberti, M. Figini, S. Canevari, and F. Tedesco Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res., April 1, 2006; 66(7): 3876 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Buchsbaum, M.B. Khazaeli, D. B. Axworthy, J. Schultz, T. R. Chaudhuri, K. R. Zinn, M. Carpenter, and A. F. LoBuglio Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein Clin. Cancer Res., November 15, 2005; 11(22): 8180 - 8185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Berndorff, S. Borkowski, S. Sieger, A. Rother, M. Friebe, F. Viti, C. S. Hilger, J. E. Cyr, and L. M. Dinkelborg Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate Clin. Cancer Res., October 1, 2005; 11(19): 7053s - 7063s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Kriegeskorte, F. E. Gebhardt, S. Porcellini, M. Schiemann, C. Stemberger, T. J. Franz, K. M. Huster, L. N. Carayannopoulos, W. M. Yokoyama, M. Colonna, et al. NKG2D-independent suppression of T cell proliferation by H60 and MICA PNAS, August 16, 2005; 102(33): 11805 - 11810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Nordlund, V. P. Hytonen, O. H. Laitinen, and M. S. Kulomaa Novel Avidin-like Protein from a Root Nodule Symbiotic Bacterium, Bradyrhizobium japonicum J. Biol. Chem., April 8, 2005; 280(14): 13250 - 13255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, et al. Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin Clin. Cancer Res., May 1, 2004; 10(9): 3137 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mamede, T. Saga, H. Kobayashi, T. Ishimori, T. Higashi, N. Sato, M. W. Brechbiel, and J. Konishi Radiolabeling of Avidin with Very High Specific Activity for Internal Radiation Therapy of Intraperitoneally Disseminated Tumors Clin. Cancer Res., September 1, 2003; 9(10): 3756 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Lewis, M. Wang, D. B. Axworthy, L. J. Theodore, R. W. Mallet, A. R. Fritzberg, M. J. Welch, and C. J. Anderson In Vivo Evaluation of Pretargeted 64Cu for Tumor Imaging and Therapy J. Nucl. Med., August 1, 2003; 44(8): 1284 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pagel, N. Hedin, K. Subbiah, D. Meyer, R. Mallet, D. Axworthy, L. J. Theodore, D. S. Wilbur, D. C. Matthews, and O. W. Press Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas Blood, March 15, 2003; 101(6): 2340 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. C. Boerman, F. G. van Schaijk, W. J.G. Oyen, and F. H.M. Corstens Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step J. Nucl. Med., March 1, 2003; 44(3): 400 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Zhang, K. Garmestani, J. Schultz, D. B. Axworthy, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts PNAS, February 18, 2003; 100(4): 1891 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yao, M. Zhang, D. B. Axworthy, K. J. Wong, K. Garmestani, L. Park, C. W. Park, R. W. Mallett, L. J. Theodore, E. K. Yau, et al. Radioimmunotherapy of A431 Xenografted Mice with Pretargeted B3 Antibody-Streptavidin and 90Y-labeled 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid (DOTA)-Biotin Cancer Res., October 15, 2002; 62(20): 5755 - 5760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Yao, K. Garmestani, D. B. Axworthy, Z. Zhang, R. W. Mallett, L. J. Theodore, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213 Blood, June 17, 2002; 100(1): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Chang, R. M. Sharkey, E. A. Rossi, H. Karacay, W. McBride, H. J. Hansen, J.-F. Chatal, J. Barbet, and D. M. Goldenberg Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies Mol. Cancer Ther., May 1, 2002; 1(7): 553 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Perico, M. Chinol, A. Nacca, E. Luison, G. Paganelli, and S. Canevari The Humoral Immune Response to Macrocyclic Chelating Agent DOTA Depends on the Carrier Molecule J. Nucl. Med., November 1, 2001; 42(11): 1697 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Reali, J. W. Greiner, A. Corti, H. J. Gould, F. Bottazzoli, G. Paganelli, J. Schlom, and A. G. Siccardi IgEs Targeted on Tumor Cells: Therapeutic Activity and Potential in the Design of Tumor Vaccines Cancer Res., July 1, 2001; 61(14): 5517 - 5522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guttinger, F. Guidi, M. Chinol, E. Reali, F. Veglia, G. Viale, G. Paganelli, A. Corti, and A. G. Siccardi Adoptive Immunotherapy by Avidin-driven Cytotoxic T Lymphocyte- Tumor Bridging Cancer Res., August 1, 2000; 60(15): 4211 - 4215. [Abstract] [Full Text]
|
|
|
|
|
|
A. Gasparri, M. Moro, F. Curnis, A. Sacchi, S. Pagano, F. Veglia, G. Casorati, A. G. Siccardi, P. Dellabona, and A. Corti Tumor Pretargeting with Avidin Improves the Therapeutic Index of Biotinylated Tumor Necrosis Factor {{alpha}} in Mouse Models Cancer Res., June 1, 1999; 59(12): 2917 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Lanza, K. D. Wallace, M. J. Scott, W. P. Cacheris, D. R. Abendschein, D. H. Christy, A. M. Sharkey, J. G. Miller, P. J. Gaffney, and S. A. Wickline A Novel Site-Targeted Ultrasonic Contrast Agent With Broad Biomedical Application Circulation, December 15, 1996; 94(12): 3334 - 3340. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
